Expression profiling of leukemia patients: Key lessons and future directions

Experimental Hematology

Volumn 42, Issue 8, 2014, Pages 651-660

  Shivarov, Velizar ^a   Bullinger, Lars ^b  

^a National Hematology Hospital   (Bulgaria)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 10A; MICRORNA 10B; MICRORNA 126; MICRORNA 127; MICRORNA 128; MICRORNA 130A; MICRORNA 17; MICRORNA 181B; MICRORNA 204; MICRORNA 299; MICRORNA 323; MICRORNA 368; MICRORNA 382; MICRORNA 451; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALTERNATIVE RNA SPLICING; BINDING SITE; CANCER SURVIVAL; DNA METHYLATION; DOWN REGULATION; FLT3 ITD GENE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA CELL; NONHUMAN; ONCOGENE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA BINDING; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; U2AF1 GENE; UPREGULATION;

ALTERNATIVE SPLICING; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SINGLE-CELL ANALYSIS;

EID: 84905163247     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.04.006     Document Type: Review

References (96)

1. Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
2. Chen J., Odenike O., Rowley J.D. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010, 10:23-36.
3. Estey E., Dohner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
4. Bullinger L., Valk P.J.M. Gene expression profiling in acute myeloid leukemia. J Clin Oncol 2005, 23:6296-6305.
5. Theilgaard-Monch K., Boultwood J., Ferrari S., et al. Gene expression profiling in MDS and AML: potential and future avenues. Leukemia 2011, 25:909-920.
6. Wouters B.J., Lowenberg B., Delwel R. A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 2009, 113:291-298.
7. Bacher U., Kohlmann A., Haferlach C., Haferlach T. Gene expression profiling in acute myeloid leukaemia (AML). Best Pract Res Clin Haematol 2009, 22:169-180.
8. Bullinger L., Dohner K., Bair E., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004, 350:1605-1616.
9. Bullinger L., Rucker F.G., Kurz S., et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007, 110:1291-1300.
10. Luck S.C., Russ A.C., Du J., et al. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. Br J Haematol 2010, 148:925-937.
11. Valk P.J., Verhaak R.G., Beijen M.A., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-1628.
12. Wilson C.S., Davidson G.S., Martin S.B., et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 2006, 108:685-696.
13. Wouters B.J., Löwenberg B., Erpelinck-Verschueren C.A.J., Van Putten W.L.J., Valk P.J.M., Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113:3088-3091.
14. Haferlach T., Kohlmann A., Wieczorek L., et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010, 28:2529-2537.
15. Li Z., Huang H., Li Y., et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood 2012, 119:2314-2324.
16. Bullinger L., Döhner K., Bair E., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004, 350:1605-1616.
17. Garzon R., Garofalo M., Martelli M.P., et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008, 105:3945-3950.
18. Verhaak R.G.W., Goudswaard C.S., Van Putten W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005, 106:3747-3754.
19. Wouters B.J., Jordà M.A., Keeshan K., et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007, 110:3706-3714.
20. Bullinger L., Döhner K., Kranz R., et al. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 2008, 111:4490-4495.
21. Marcucci G., Maharry K., Wu Y.Z., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010 May 10, 28:2348-2355.
22. Metzeler K.H., Maharry K., Radmacher M.D., et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011, 29:1373-1381.
23. Gaidzik V.I., Paschka P., Spath D., et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 2012, 30:1350-1357.
24. Metzeler K.H., Becker H., Maharry K., et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011, 118:6920-6929.
25. Gaidzik V.I., Bullinger L., Schlenk R.F., et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011, 29:1364-1372.
26. Kohlmann A., Bullinger L., Thiede C., et al. Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia 2010, 24:1216-1220.
27. Radmacher M.D., Marcucci G., Ruppert A.S., et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 2006, 108:1677-1683.
28. Metzeler K.H., Hummel M., Bloomfield C.D., et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008, 112:4193-4201.
29. Li Z., Herold T., He C., et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol 2013, 31:1172-1181.
30. Lacayo N.J., Meshinchi S., Kinnunen P., et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 2004, 104:2646-2654.
31. Bresolin S., Zecca M., Flotho C., et al. Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. J Clin Oncol 2010, 28:1919-1927.
32. Eppert K., Takenaka K., Lechman E.R., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011, 17:1086-1093.
33. Metzeler K.H., Maharry K., Kohlschmidt J., et al. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia 2013, 27:2023-2031.
34. Miller B.G., Stamatoyannopoulos J.A. Integrative meta-analysis of differential gene expression in acute myeloid leukemia. PLoS One 2010, 5:e9466.
35. Papaemmanuil E., Cazzola M., Boultwood J., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365:1384-1395.
36. Yoshida K., Sanada M., Shiraishi Y., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
37. Makishima H., Visconte V., Sakaguchi H., et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012, 119:3203-3210.
38. Dolnik A., Engelmann J.C., Scharfenberger-Schmeer M., et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood 2012, 120:e83-e92.
39. Dallosso A.R., Hancock A.L., Malik S., et al. Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer. RNA 2007, 13:2287-2299.
40. Adamia S., Haibe-Kains B., Pilarski P.M., et al. A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res 2014, 20:1135.
41. Sammeth M., Foissac S., Guigo R. A general definition and nomenclature for alternative splicing events. PLoS Comput Biol 2008, 4:e1000147.
42. Adamia S., Bar-Natan M., Haibe-Kains B., et al. NOTCH2 and FLT3 gene mis-splicing are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood 2014, 123:2816-2825.
43. Brooks A.N., Choi P.S., de Waal L., et al. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One 2014, 9:e87361.
44. Przychodzen B., Jerez A., Guinta K., et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood 2013, 122:999-1006.
45. Bernstein B.E., Birney E., Dunham I., Green E.D., Gunter C., Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74.
46. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
47. Bartel D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136:215-233.
48. Raghavachari N., Liu P., Barb J.J., et al. Integrated analysis of miRNA and mRNA during differentiation of human CD34+ cells delineates the regulatory roles of microRNA in hematopoiesis. Exp Hematol 2014, 42:14-27.e1-2.
49. Havelange V., Garzon R., Croce C.M. MicroRNAs: New players in acute myeloid leukaemia. Br J Cancer 2009, 101:743-748.
50. Wieser R., Scheideler M., Hackl H., et al. MicroRNAs in acute myeloid leukemia: expression patterns, correlations with genetic and clinical parameters, and prognostic significance. Genes Chromosomes Cancer 2010, 49:193-203.
51. Marcucci G., Mrozek K., Radmacher M.D., Garzon R., Bloomfield C.D. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011, 117:1121-1129.
52. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
53. Li Z., Lu J., Sun M., et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 2008, 105:15535-15540.
54. Jongen-Lavrencic M., Sun S.M., Dijkstra M.K., Valk P.J., Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008, 111:5078-5085.
55. Dixon-McIver A., East P., Mein C.A., et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 2008, 3:e2141.
56. Marcucci G., Radmacher M.D., Maharry K., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1919-1928.
57. Russ A.C., Sander S., Luck S.C., et al. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA-target gene interactions in acute myeloid leukemia. Haematologica 2011, 96:1783-1791.
58. Garzon R., Volinia S., Liu C.G., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:3183-3189.
59. Marcucci G., Maharry K., Radmacher M.D., et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008, 26:5078-5087.
60. Pulikkan J.A., Peramangalam P.S., Dengler V., et al. C/EBPalpha regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood 2010, 116:5638-5649.
61. Mendler J.H., Maharry K., Radmacher M.D., et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol 2012, 30:3109-3118.
62. Marcucci G., Metzeler K.H., Schwind S., et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012, 30:742-750.
63. Langer C., Marcucci G., Holland K.B., et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2009, 27:3198-3204.
64. Schwind S., Maharry K., Radmacher M.D., et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28:5257-5264.
65. Zhang H., Luo X.Q., Zhang P., et al. MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One 2009, 4:e7826.
66. Marcucci G., Maharry K.S., Metzeler K.H., et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013, 31:2086-2093.
67. Diaz-Beya M., Brunet S., Nomdedeu J., et al. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia 2014, 28:804-812.
68. Grasedieck S., Sorrentino A., Langer C., et al. Circulating microRNAs in hematological diseases: principles, challenges, and perspectives. Blood 2013, 121:4977-4984.
69. Grasedieck S., Scholer N., Bommer M., et al. Impact of serum storage conditions on microRNA stability. Leukemia 2012, 26:2414-2416.
70. Fayyad-Kazan H., Bitar N., Najar M., et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med 2013, 11:31.
71. Tanaka M., Oikawa K., Takanashi M., et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009, 4:e5532.
72. Zhi F., Cao X., Xie X., et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS One 2013, 8:e56718.
73. Kuchenbauer F., Mah S.M., Heuser M., et al. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood 2011, 118:3350-3358.
74. Garitano-Trojaola A., Agirre X., Prosper F., Fortes P. Long non-coding RNAs in haematological malignancies. Int J Mol Sci 2013, 14:15386-15422.
75. Memczak S., Jens M., Elefsinioti A., et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013, 495:333-338.
76. Bamezai S., Rawat V.P., Buske C. Concise review: The Piwi-piRNA axis: Pivotal beyond transposon silencing. Stem Cells 2012, 30:2603-2611.
77. Tay Y., Rinn J., Pandolfi P.P. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014, 505:344-352.
78. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066.
79. Wang Z., Gerstein M., Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009, 10:57-63.
80. Ozsolak F., Milos P.M. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 2011, 12:87-98.
81. Battke F., Nieselt K. Mayday SeaSight: combined analysis of deep sequencing and microarray data. PLoS One 2011, 6:e16345.
82. Miller C.A., Wilson R.K., Ley T.J. Genomic landscapes and clonality of de novo AML. N Engl J Med 2013, 369:1473.
83. Figueroa M.E., Lugthart S., Li Y., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.
84. Bullinger L., Ehrich M., Dohner K., et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010, 115:636-642.
85. Marcucci G., Yan P., Maharry K., et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol 2014, 32:548-556.
86. Hebestreit K., Dugas M., Klein H.U. Detection of significantly differentially methylated regions in targeted bisulfite sequencing data. Bioinformatics 2013, 29:1647-1653.
87. Joshi A., Hannah R., Diamanti E., Gottgens B. Gene set control analysis predicts hematopoietic control mechanisms from genome-wide transcription factor binding data. Exp Hematol 2013, 41:354-366.e14.
88. Welch J.S., Ley T.J., Link D.C., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150:264-278.
89. Jan M., Snyder T.M., Corces-Zimmerman M.R., et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012, 4:149ra18.
90. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
91. Shackleton M., Quintana E., Fearon E.R., Morrison S.J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
92. Bendall S.C., Nolan G.P. From single cells to deep phenotypes in cancer. Nat Biotechnol 2012, 30:639-647.
93. Moignard V., Macaulay I.C., Swiers G., et al. Characterization of transcriptional networks in blood stem and progenitor cells using high-throughput single-cell gene expression analysis. Nat Cell Biol 2013, 15:363-372.
94. Guo G., Luc S., Marco E., et al. Mapping cellular hierarchy by single-cell analysis of the cell surface repertoire. Cell Stem Cell 2013, 13:492-505.
95. Schwind S., Marcucci G., Kohlschmidt J., et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 2011, 118:4188-4198.
96. Schwind S., Marcucci G., Maharry K., et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010, 116:5660-5669.